These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19362953)

  • 1. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management.
    Tsimboukis S; Merikas I; Karapanagiotou EM; Saif MW; Syrigos KN
    Clin Lung Cancer; 2009 Mar; 10(2):106-11. PubMed ID: 19362953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sparing of previously irradiated skin from erlotinib-induced acneiform rash.
    Yalçin S; Dizdar O; Yalçin B; Gököz O
    J Am Acad Dermatol; 2008 Jan; 58(1):178-9. PubMed ID: 18158935
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
    Peréz-Soler R; Saltz L
    J Clin Oncol; 2005 Aug; 23(22):5235-46. PubMed ID: 16051966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.
    Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
    Lung Cancer; 2012 Oct; 78(1):8-15. PubMed ID: 22795701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
    Gridelli C; Maione P; Amoroso D; Baldari M; Bearz A; Bettoli V; Cammilluzzi E; Crinò L; De Marinis F; Di Pietro FA; Grossi F; Innocenzi D; Micali G; Piantedosi FV; Scartozzi M
    Crit Rev Oncol Hematol; 2008 May; 66(2):155-62. PubMed ID: 18083041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
    Kiyohara Y; Yamazaki N; Kishi A
    J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
    Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.
    Bidoli P; Cortinovis DL; Colombo I; Crippa A; Cicchiello F; Villa F; Cazzaniga ME; Altomare G
    J Thorac Oncol; 2010 Oct; 5(10):1662-3. PubMed ID: 20871265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
    Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
    Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
    Pérez-Soler R
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):23-8. PubMed ID: 14682120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
    Pérez-Soler R; Chachoua A; Hammond LA; Rowinsky EK; Huberman M; Karp D; Rigas J; Clark GM; Santabárbara P; Bonomi P
    J Clin Oncol; 2004 Aug; 22(16):3238-47. PubMed ID: 15310767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
    de Marinis F; Vergnenegre A; Passaro A; Dubos-Arvis C; Carcereny E; Drozdowskyj A; Zeaiter A; Perez-Moreno P; Rosell R
    Future Oncol; 2015; 11(3):421-9. PubMed ID: 25675123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?
    Giuliani J; Marzola M
    Arch Dermatol Res; 2013 Sep; 305(7):653-8. PubMed ID: 23536039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
    Perez-Soler R
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bexarotene and erlotinib for aerodigestive tract cancer.
    Dragnev KH; Petty WJ; Shah S; Biddle A; Desai NB; Memoli V; Rigas JR; Dmitrovsky E
    J Clin Oncol; 2005 Dec; 23(34):8757-64. PubMed ID: 16314636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.
    Luu M; Boone SL; Patel J; Sullivan P; Rademaker AW; Balagula Y; Lacouture ME
    Clin Exp Dermatol; 2011 Oct; 36(7):733-8. PubMed ID: 21689147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Iyer R; Bharthuar A
    Expert Opin Pharmacother; 2010 Feb; 11(2):311-20. PubMed ID: 20088749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 20. Identifying predictive and surrogate markers of erlotinib antitumor activity other than rash.
    Soulières D
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):29-33. PubMed ID: 14682121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.